美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

三倍做多标普生物-Direxion

337.89

+29.569.59%

成交量：32.04万

成交额：1.07亿

市值：7.18亿

市盈率：- -

高：340.20

开：318.40

低：318.40

收：308.33

52周最高：341.93

52周最低：66.95

股本：212.45万

流通股本：212.45万

量比：2.00

换手率：15.08%

股息：1.02

股息率：0.30%

净资产收益率：--

总资产收益率：--

市净率：--

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

和谐健康保险孝感中支被罚18万，涉编制虚假资料

医疗保健板块市场快讯汇总

把肿瘤变成“原位疫苗”!Replimune(REPL.US)溶瘤病毒闯过FDA，PD-1耐药黑色素瘤迎来新一代免疫重启方案

北京经济技术开发区：鼓励具身智能、自动驾驶、医疗健康等重点领域数据交易流通每年发放1亿元数据券

医疗保健板块市场动态综述

医疗板块市场动态速览

构建社保商保分层协同机制，破解创新药支付困境——商业医疗保险与创新药支付管理研讨会在京召开

Moderna研发的首款mRNA流感疫苗获FDA批准

莫德纳首款mRNA流感疫苗获FDA批准

莫德纳首款mRNA流感疫苗获FDA批准

环球市场播报

武田制药Orzeyful获FDA批准，用于治疗1型发作性睡病

医疗保健板块动态：市场快评

医疗保健板块快讯：市场动态一览

医疗保健板块动态：市场快评

医疗保健板块动态：市场快评

上海国投先导联合领投，NewPro完成数千万元PreA轮融资并获得乳铁蛋白FDA Self-GRAS认证

FDA授予Xellsmart帕金森病现货型细胞疗法快速通道资格

环球市场播报

艾伯维（ABBV）保妥适新适应症获FDA受理有望成美国首款咬肌突出医美肉毒制剂

海西新药(02637.HK)：HX9428治疗新生血管性年龄相关性黄斑变性获美国FDA IND批准启动II期临床试验同时在中国启动第二项采用阳性对照的II期临床试验

海西新药(02637)：HX9428治疗新生血管性年龄相关性黄斑变性获美国FDA IND批准启动II期临床试验同时在中国启动第二项采用阳性对照的II期临床试验

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/stock/LABU/news?page=5"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LABU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","market":"US","secType":"STK","nameCN":"三倍做多标普生物-Direxion","latestPrice":337.885,"timestamp":1787671985939,"preClose":308.33,"halted":0,"volume":320422,"delay":0,"changeRate":0.09585509032530085,"floatShares":2124486,"shares":2124486,"eps":0,"marketStatus":"交易中","change":29.555,"latestTime":"08-25 11:33:09 EDT","open":318.4,"high":340.1999,"low":318.4,"amount":106690560.87580001,"amplitude":0.070703,"askPrice":338.43,"askSize":40,"bidPrice":337.54,"bidSize":25,"shortable":3,"etf":3,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1787688000000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":308.33,"sharesOutstanding":3074486,"nav":316.946,"aum":673347221.03,"dividendRate":0.003011,"bidAskSpread":0.002803,"preHourTrading":{"tag":"盘前","latestPrice":320.4,"preClose":308.33,"latestTime":"09:29 EDT","volume":4090,"amount":1297999.7005999999,"timestamp":1787664599999,"change":12.07,"changeRate":0.039146,"amplitude":0.037817},"postHourTrading":{"tag":"盘后","latestPrice":308.6,"preClose":308.33,"latestTime":"19:56 EDT","volume":2524,"amount":779026.005,"timestamp":1787615773057,"change":0.27,"changeRate":0.000876,"amplitude":0.011327},"volumeRatio":1.998461,"impliedVol":1.0129,"impliedVolPercentile":0.8805},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","floatShares":2124486,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.998461,"shares":2124486,"dividePrice":1.0175,"high":340.1999,"amplitude":0.070703,"preClose":308.33,"low":318.4,"week52Low":66.95,"pbRate":"--","week52High":341.93,"institutionHeld":0,"latestPrice":337.885,"committee":-0.230769,"eps":0,"divideRate":0.003011,"volume":320422,"delay":0,"ttmEps":0,"open":318.4,"prevYearClose":159.39,"prevWeekClose":317.2,"prevMonthClose":227.4,"prevQuarterClose":292.1,"fiveDayClose":289.98,"twentyDayClose":242,"sixtyDayClose":195.3},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LABU\",params:#limit:5,,,undefined,":[{"date":"2025-09-23","symbol":"LABU","amount":0.10273,"announcedDate":"2025-09-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-23","defaultRemindTime":1758634200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-23","currency":"USD","dateTimestamp":1758600000000,"payDate":"2025-09-30"},{"date":"2025-06-24","symbol":"LABU","amount":0.21897,"announcedDate":"2025-06-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-24","defaultRemindTime":1750771800000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-24","currency":"USD","dateTimestamp":1750737600000,"payDate":"2025-07-01"},{"date":"2025-03-25","symbol":"LABU","amount":0.10714,"announcedDate":"2025-03-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-25","defaultRemindTime":1742909400000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-25","currency":"USD","dateTimestamp":1742875200000,"payDate":"2025-04-01"},{"date":"2024-06-25","symbol":"LABU","amount":0.15021,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-25","defaultRemindTime":1719322200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-02","payableDate":"2024-06-25","currency":"USD","dateTimestamp":1719288000000,"payDate":"2024-07-02"},{"date":"2024-03-19","symbol":"LABU","amount":0.16064,"announcedDate":"2024-03-18","type":"dividend","market":"US","newRecordDate":"2024-03-20","defaultRemindTime":1710855000000,"name":"三倍做多标普生物-Direxion","recordDate":"2024-03-26","payableDate":"2024-03-20","currency":"USD","dateTimestamp":1710820800000,"payDate":"2024-03-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LABU\",market:\"US\",,,undefined,":[{"executeDate":"2018-06-19","recordDate":"2018-06-20","paymentDate":"2018-06-26","value":0.01932,"currency":"USD"},{"executeDate":"2018-09-25","recordDate":"2018-09-26","paymentDate":"2018-10-02","value":0.0954,"currency":"USD"},{"executeDate":"2018-12-27","recordDate":"2018-12-28","paymentDate":"2019-01-04","value":0.09621,"currency":"USD"},{"executeDate":"2019-03-19","recordDate":"2019-03-20","paymentDate":"2019-03-26","value":0.10973,"currency":"USD"},{"executeDate":"2019-06-25","recordDate":"2019-06-26","paymentDate":"2019-07-02","value":0.03745,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LABU\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LABU\",pageSize:20,pageCount:5,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2657617229","title":"和谐健康保险孝感中支被罚18万，涉编制虚假资料","url":"https://stock-news.laohu8.com/highlight/detail?id=2657617229","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657617229?lang=zh_cn&edition=fundamental","pubTime":"2026-08-07 18:58","pubTimestamp":1786100322,"startTime":"0","endTime":"0","summary":"蓝鲸新闻8月7日讯，近日，孝感金融监管分局发布行政处罚决定书，剑指和谐健康保险股份有限公司孝感中心支公司及相关责任人。罚单显示，和谐健康保险股份有限公司孝感中心支公司的主要违法违规行为是：编制虚假资料。针对上述违法行为，孝感金融监管分局对和谐健康保险股份有限公司孝感中心支公司罚款18万元，对李婷警告并罚款2.5万元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1786096518804106658","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["LABU","XLV","BK4581","BK4585","BK4588","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129560773","title":"医疗保健板块市场快讯汇总","url":"https://stock-news.laohu8.com/highlight/detail?id=1129560773","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129560773?lang=zh_cn&edition=fundamental","pubTime":"2026-08-07 16:22","pubTimestamp":1786090970,"startTime":"0","endTime":"0","summary":"投资者在美国就业数据和中东局势谈判消息出炉前保持观望态度。泛欧斯托克600指数微涨0.2%，软件与医疗保健板块领涨。伦敦富时100指数同样小幅上扬0.2%，国际油价企稳带动石油巨头走强。帝亚吉欧延续涨势，股价已连续第二个交易日攀升，目前涨幅达1.5%。软件巨头SAP攀升3.5%，但戴姆勒卡车控股公司在发布财报后下跌2.9%。意大利富时MIB指数基本持平，而西班牙IBEX 35指数因银行股走弱而微跌0.3%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","XLV","BK4588","LABU","BK4585","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657904156","title":"把肿瘤变成“原位疫苗”!Replimune(REPL.US)溶瘤病毒闯过FDA，PD-1耐药黑色素瘤迎来新一代免疫重启方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2657904156","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657904156?lang=zh_cn&edition=fundamental","pubTime":"2026-08-07 14:59","pubTimestamp":1786085956,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LABU","LU1169590202.USD","BK4585","BK4588","LU1169589451.USD","BK4139","REPL","BK4023","PD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657965566","title":"北京经济技术开发区：鼓励具身智能、自动驾驶、医疗健康等重点领域数据交易流通 每年发放1亿元数据券","url":"https://stock-news.laohu8.com/highlight/detail?id=2657965566","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657965566?lang=zh_cn&edition=fundamental","pubTime":"2026-08-07 12:34","pubTimestamp":1786077245,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["KOMP","HAIL","BK4581","XLV","XBI","BK4550","IXJ","FDIF","NBDS","WDRN","IQM","FAI","CARZ","XT","MOTO","DRIV","TARK","IDRV","BK4588","ROBT","BK4585","VHT","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160721676","title":"医疗保健板块市场动态综述","url":"https://stock-news.laohu8.com/highlight/detail?id=1160721676","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160721676?lang=zh_cn&edition=fundamental","pubTime":"2026-08-07 00:25","pubTimestamp":1786033543,"startTime":"0","endTime":"0","summary":"0739 ET - 伦敦上市制药商Hikma Pharmaceuticals上半年业绩表现强劲，但其对全年业绩的展望却显得颇为保守，并未随之上调，这令市场感到意外。这一积极表现主要得益于Hikma旗下品牌药部门的强劲增长，预计将受到投资者的欢迎。然而，即便上半年核心运营利润率大幅改善，Hikma仍坚持其2026年全年核心运营利润指引，即7.2亿至7.7亿美元，这一区间与市场普遍预期的7.31亿美元相比，并未显得更为乐观。受此消息影响，公司股价大涨10%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLV","BK4581","BK4585","XBI","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137064261","title":"医疗板块市场动态速览","url":"https://stock-news.laohu8.com/highlight/detail?id=1137064261","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137064261?lang=zh_cn&edition=fundamental","pubTime":"2026-08-06 16:26","pubTimestamp":1786004808,"startTime":"0","endTime":"0","summary":"1655 GMT - 礼来公司CEO David Ricks在CNBC上表示，该公司近期推出的每日一次GLP-1口服药Foundayo，尽管定价更低，但正在扩大市场而非蚕食现有市场。与此同时，减肥治疗的覆盖面持续扩大，进一步拓宽了潜在市场总规模。这些利好因素增强了礼来公司的信心，使其将营收预期从820亿至850亿美元上调至850亿至870亿美元。礼来股价目前上涨3%。市场对GLP-1减肥药的持续强劲需求推动第二季度营收跃升48%，达到229.7亿美元，超出预期的206.9亿美元。诺和诺德股价下跌4%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LABU","BK4581","XLV","XBI","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657669688","title":"构建社保商保分层协同机制，破解创新药支付困境——商业医疗保险与创新药支付管理研讨会在京召开","url":"https://stock-news.laohu8.com/highlight/detail?id=2657669688","media":"金融一线","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657669688?lang=zh_cn&edition=fundamental","pubTime":"2026-08-06 14:55","pubTimestamp":1785999300,"startTime":"0","endTime":"0","summary":"专题：新浪健康保险研究院2026年7月31日，由中央财经大学保险学院主办、新浪健康保险研究院协办的“商业医疗保险与创新药支付管理研讨会”在京举行。因此，在医保基金收支承压、商业保险资金池有限、天价药风险集中的现实约束下，造成创新药支付困境凸显。商保在创新药上市早期的支付补充价值。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/insurance/bxyy/2026-08-06/doc-inimkfvm3890828.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LNGR","BK4581","BK4588","XLV","BK1161","IBBQ","MEDX","06978","159992","BK4585","LABU","BK1574","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657232501","title":"Moderna研发的首款mRNA流感疫苗获FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2657232501","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657232501?lang=zh_cn&edition=fundamental","pubTime":"2026-08-06 13:20","pubTimestamp":1785993606,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LABU","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657917506","title":"莫德纳首款mRNA流感疫苗获FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2657917506","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657917506?lang=zh_cn&edition=fundamental","pubTime":"2026-08-06 11:44","pubTimestamp":1785987861,"startTime":"0","endTime":"0","summary":"来源：环球市场播报美国食品药品管理局批准了莫德纳针对50岁及以上成人的mRNA流感疫苗。这款名为mFlusiva的疫苗采用了与莫德纳新冠疫苗相同的mRNA技术。今年2月，FDA最初直接拒绝审查莫德纳的申请。莫德纳对FDA 2月份的决定感到意外。几天后，莫德纳提出了一份包含另一项试验的修订计划，FDA随后改变了立场。即使获得FDA批准，该疫苗的商业前景依然存在不确定性。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2026/08/06114458030151.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["BK4588","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657051935","title":"莫德纳首款mRNA流感疫苗获FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2657051935","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657051935?lang=zh_cn&edition=fundamental","pubTime":"2026-08-06 11:09","pubTimestamp":1785985740,"startTime":"0","endTime":"0","summary":"美国食品药品管理局批准了莫德纳针对50岁及以上成人的mRNA流感疫苗。这款名为mFlusiva的疫苗采用了与莫德纳新冠疫苗相同的mRNA技术。今年2月，FDA最初直接拒绝审查莫德纳的申请。莫德纳对FDA 2月份的决定感到意外。几天后，莫德纳提出了一份包含另一项试验的修订计划，FDA随后改变了立场。即使获得FDA批准，该疫苗的商业前景依然存在不确定性。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-08-06/doc-inimivfi3151001.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4585","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657220495","title":"武田制药Orzeyful获FDA批准，用于治疗1型发作性睡病","url":"https://stock-news.laohu8.com/highlight/detail?id=2657220495","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657220495?lang=zh_cn&edition=fundamental","pubTime":"2026-08-06 03:55","pubTimestamp":1785959722,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["TAK","BK4588","BK4007","BK4585","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198057342","title":"医疗保健板块动态：市场快评","url":"https://stock-news.laohu8.com/highlight/detail?id=1198057342","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198057342?lang=zh_cn&edition=fundamental","pubTime":"2026-08-06 00:29","pubTimestamp":1785947351,"startTime":"0","endTime":"0","summary":"最新医疗保健板块市场快讯，本报道仅在道琼斯通讯社于美东时间4:20、12:20及16:50独家发布。0429 ET - 伯恩斯坦分析师指出，诺和诺德第二季度财报表现超预期，并上调了业绩指引，但这对市场普遍预期的中值调整幅度微乎其微。Wegovy口服药的销售额低于市场预期，但公司强调，差异源于去库存行为。在哥本哈根，诺和诺德在财报公布后下跌4.4%。该股持平于1.06林吉特。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VOTE","LABU","XLV","BK4581","FEBU","BK4585","BK4588","JOYT","XBI","PMDE","GXDW","RGLO","VGFPF","DECU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176091087","title":"医疗保健板块快讯：市场动态一览","url":"https://stock-news.laohu8.com/highlight/detail?id=1176091087","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176091087?lang=zh_cn&edition=fundamental","pubTime":"2026-08-05 16:28","pubTimestamp":1785918487,"startTime":"0","endTime":"0","summary":"0736 GMT - 杰富瑞分析师在一份研究报告中指出，德国医疗保健集团费森尤斯正上调全年盈利指引，这得益于其Kabi制药部门增长驱动力的盈利能力提升。分析师表示，费森尤斯旗下Kabi业务在第二季度实现了17%的调整后营业利润率，其增长向量的利润率首次进入17%至19%的区间。此外，分析人士认为，德国医疗保健改革的获批，为集团旗下Helios医院部门消除了监管不确定性。费森尤斯股价上涨5.6%。在哥本哈根，诺和诺德在公布财报后下跌4.4%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","XLV","GXDW","BK4585","VGFPF","XBI","DECU","VOTE","PMDE","RGLO","BK4588","JOYT","FEBU","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151299937","title":"医疗保健板块动态：市场快评","url":"https://stock-news.laohu8.com/highlight/detail?id=1151299937","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151299937?lang=zh_cn&edition=fundamental","pubTime":"2026-08-05 04:57","pubTimestamp":1785877040,"startTime":"0","endTime":"0","summary":"1038 ET - 摩根大通分析师指出，葛兰素史克新近推出的药物，将是降低这家英国药企明年前景风险的关键。葛兰素史克近期推出了血癌药物Blenrep和哮喘治疗药物Exdensur，而通过收购Nuvalent获得的肺癌药物Jideytro，也在上月获得美国批准。0123 ET - 摩根大通分析师在一份研究报告中表示，费森尤斯医疗第二季度业绩超出市场预期，但该公司重申全年业绩指引，暗示未来几个季度盈利可能收缩。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLV","LABU","XBI","BK4588","BK4585","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122423549","title":"医疗保健板块动态：市场快评","url":"https://stock-news.laohu8.com/highlight/detail?id=1122423549","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122423549?lang=zh_cn&edition=fundamental","pubTime":"2026-08-05 00:26","pubTimestamp":1785860812,"startTime":"0","endTime":"0","summary":"**GSK新品上市，能否化解明年风险？GSK近期推出了血癌药物Blenrep和哮喘治疗药Exdensur，而通过收购Nuvalent获得的肺癌药物Jideytro，上月也已获得美国批准。0123 ET - 摩根大通分析师在研报中表示，费森尤斯医疗第二季度业绩超出市场预期，但公司重申全年指引，暗示未来几个季度盈利可能收缩。这家德国透析专科公司公布的季度调整后营业利润为5.69亿欧元，高于市场普遍预期的5.14亿欧元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","XLV","LABU","BK4581","XBI","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656554061","title":"上海国投先导联合领投，NewPro完成数千万元PreA轮融资并获得乳铁蛋白FDA Self-GRAS认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2656554061","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656554061?lang=zh_cn&edition=fundamental","pubTime":"2026-08-04 22:18","pubTimestamp":1785853106,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LABU","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656875551","title":"FDA授予Xellsmart帕金森病现货型细胞疗法快速通道资格","url":"https://stock-news.laohu8.com/highlight/detail?id=2656875551","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656875551?lang=zh_cn&edition=fundamental","pubTime":"2026-08-04 21:07","pubTimestamp":1785848846,"startTime":"0","endTime":"0","summary":"XellSmart专有的现货型iPSC衍生细胞疗法XS411获得美国FDA快速通道资格，标志着其全球临床开发的重要里程碑。　　2026年7月28日，XellSmart宣布，其自主研发的针对帕金森病的同种异体、现货型、可注射iPSC衍生细胞疗法候选产品XS411，已正式获得美国食品药品监督管理局授予的快速通道资格。这一监管认定彰显了美国卫生监管机构对XS411临床价值及其解决帕金森病治疗中重大未满足临床需求潜力的认可，是其全球临床开发和未来市场准入的关键里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-08-04/doc-inimeknz5555117.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["WDNA","CNCR","LABU","BK4585","SYNB","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656597285","title":"艾伯维（ABBV）保妥适新适应症获FDA受理 有望成美国首款咬肌突出医美肉毒制剂","url":"https://stock-news.laohu8.com/highlight/detail?id=2656597285","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656597285?lang=zh_cn&edition=fundamental","pubTime":"2026-08-04 21:03","pubTimestamp":1785848630,"startTime":"0","endTime":"0","summary":"艾伯维表示，本次申报是对成熟产品潜力的进一步挖掘，以此匹配不断变化的求美者需求。作为医美赛道重磅单品，新适应症如若获批，有望进一步巩固艾尔建美学在注射医美领域的市场地位。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/NmRmY2E4Njg2ODIwNjk0NjU5Mw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NmRmY2E4Njg2ODIwNjk0NjU5Mw==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"303400","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0553294199.USD","IE000BZT7R73.USD","IE000SO60NU8.SGD","LU1989772923.USD","RXL","LU2129689431.USD","ABBV","BK4588","VHT","LU1496350502.SGD","LU1670627923.USD","LU2433249047.HKD","SG9999015952.SGD","LU2129689605.HKD","XLV","LU0965509010.AUD","PJP","FHLC","AGNG","GLAM","SG9999015945.SGD","LU0738911758.USD","PPH","LU1670628061.USD","LU0708994859.HKD","IYH","LU0158827948.USD","LU0820561818.USD","LU1989771016.USD","LU0320765646.SGD","TRUH","IE000MB6IJN5.SGD","IE00B2B36J28.USD","IE00B3PB1722.GBP","LU0912757837.SGD","LU0942090050.USD","LU2125909593.SGD","LU1430594728.SGD","LU0795875169.SGD","LU2089283258.USD","IXJ","FTXH","LU0098860793.USD","MEDX","LU0965509101.SGD","LU1989772840.SGD","JDOC","LABU","LU0289739699.SGD","LU0868494708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656539450","title":"海西新药(02637.HK)：HX9428治疗新生血管性年龄相关性黄斑变性获美国FDA IND批准启动II期临床试验 同时在中国启动第二项采用阳性对照的II期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2656539450","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656539450?lang=zh_cn&edition=fundamental","pubTime":"2026-08-04 17:15","pubTimestamp":1785834956,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BMED","IBBQ","IBBJ","PSYK","MDTX","LABU","BK4588","BK4585","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656460539","title":"海西新药(02637)：HX9428治疗新生血管性年龄相关性黄斑变性获美国FDA IND批准启动II期临床试验 同时在中国启动第二项采用阳性对照的II期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2656460539","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656460539?lang=zh_cn&edition=fundamental","pubTime":"2026-08-04 17:15","pubTimestamp":1785834956,"startTime":"0","endTime":"0","summary":"此次获批的IND涵盖一项II期临床试验方案，旨在评估HX9428不同口服剂量在美国 nAMD患者中的有效性及安全性。该研究为集团在HX9428既往I 期及II期剂量扩展研究的基础上，进一步启动的一项随机、阳性对照的II期临床研究。本次美国FDAII期临床试验获批、中国标准疗法对照II期临床试验启动，标志着 HX9428全球临床开发进程取得重要进展，为全面验证HX9428在nAMD治疗中的临床价值奠定坚实基础。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475806.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK4585","BMED","BK1191","PSYK","IND","MDTX","LABU","IBBJ","02637","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":5,"totalSize":200,"code":"91000000","status":"200"}]}}